Agency
Mercy Health-Marcum & Wallace Hospital LLC
Mercy Health-Marcum & Wallace Hospital LLC was paid $19.51M by Medicaid between Jan 2018 and Dec 2024, across 182 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoMERCY HEALTH-MARCUM & WALLACE HOSPITAL LLC
IRVINE, KY 40336
IRVINE, KY 40336
33aNPI1487643821assigned 10/18/2005
33bProvider typeEarly Intervention Provider Agency
28Total paid$19.51M
24GClaims511,168
24DCodes billed182
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Early Intervention Provider Agency providers in Kentucky
Rank by total paid#5 of 27
Median peer was paid$1.27M
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 90,594 | $3.10M | |
| 2019 | 80,881 | $3.11M | |
| 2020 | 68,188 | $2.61M | |
| 2021 | 75,892 | $2.87M | |
| 2022 | 74,335 | $2.97M | |
| 2023 | 69,143 | $2.91M | |
| 2024incomplete | 52,135 | $1.94M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 19,458 | 16,944 | $2.20M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.1% | 10,249 | 8,297 | $1.58M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 7.7% | 3,616 | 3,064 | $1.49M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.8% | 6,552 | 4,326 | $1.33M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.1% | 9,710 | 8,432 | $807K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 3,314 | 2,532 | $650K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 16,473 | 6,534 | $626K |
| 36415 | Collection of venous blood by venipuncture | 3.0% | 73,252 | 30,625 | $594K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 14,941 | 2,994 | $577K |
| 80053 | Comprehensive metabolic panel | 2.8% | 41,561 | 28,211 | $542K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.7% | 18,807 | 8,645 | $526K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 12,171 | 3,070 | $486K |
170 more codes
| 71045 | Radiologic examination, chest; single view | 2.3% | 7,742 | $446K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 867 | $399K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 8,990 | $384K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 6,154 | $365K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 7,487 | $329K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.6% | 4,819 | $315K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.6% | 12,758 | $310K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 26,237 | $302K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.4% | 4,446 | $276K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 5,130 | $262K |
| 80061 | Lipid panel | 1.3% | 11,344 | $261K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 8,169 | $237K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 7,664 | $207K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 8,072 | $204K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.0% | 2,353 | $202K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,425 | $185K |
| 73630 | <1% | 1,705 | $173K | |
| 73610 | <1% | 1,297 | $156K | |
| 73030 | <1% | 1,383 | $140K | |
| 82607 | <1% | 7,482 | $133K | |
| 73562 | <1% | 1,386 | $130K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 248 | $127K |
| 84484 | <1% | 6,360 | $121K | |
| 82746 | <1% | 6,812 | $113K | |
| 73130 | <1% | 1,009 | $110K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,792 | $105K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 616 | $102K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,730 | $92K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,807 | $90K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,500 | $89K |
| 74018 | <1% | 1,100 | $78K | |
| 72100 | <1% | 972 | $70K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 329 | $68K |
| 83880 | <1% | 1,976 | $65K | |
| 83690 | <1% | 4,845 | $62K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,493 | $51K |
| 81001 | <1% | 7,158 | $50K | |
| 97161 | <1% | 1,093 | $49K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 206 | $46K |
| 85027 | <1% | 5,022 | $42K | |
| 87040 | <1% | 2,111 | $42K | |
| 73110 | <1% | 367 | $40K | |
| 84703 | <1% | 2,732 | $39K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 463 | $39K |
| 87807 | <1% | 1,464 | $39K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,529 | $38K |
| 83735 | <1% | 3,415 | $38K | |
| 96376 | <1% | 1,228 | $35K | |
| 84439 | <1% | 1,917 | $33K | |
| 71250 | <1% | 187 | $30K | |
| 87186 | <1% | 2,133 | $30K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 752 | $30K |
| 83605 | <1% | 2,469 | $27K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 793 | $26K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 426 | $25K |
| 80074 | <1% | 425 | $24K | |
| 87077 | <1% | 3,276 | $24K | |
| 84153 | <1% | 846 | $22K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 91 | $21K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,361 | $20K |
| 85379 | <1% | 830 | $19K | |
| 87070 | <1% | 1,196 | $19K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 89 | $18K |
| 81003 | <1% | 3,021 | $17K | |
| 73502 | <1% | 268 | $17K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,209 | $17K |
| G0378 | Hospital observation service, per hour | <1% | 107 | $16K |
| 82728 | <1% | 759 | $14K | |
| 86308 | <1% | 862 | $13K | |
| 72110 | <1% | 155 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 288 | $12K |
| 86140 | <1% | 1,009 | $12K | |
| 82803 | <1% | 531 | $11K | |
| 76642 | <1% | 144 | $11K | |
| 76536 | <1% | 70 | $11K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,814 | $11K |
| 86701 | <1% | 220 | $11K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,669 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,956 | $10K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 27 | $10K |
| 86665 | <1% | 761 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,905 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,617 | $10K |
| 72040 | <1% | 156 | $10K | |
| 85610 | <1% | 1,569 | $10K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 32 | $9K |
| 12001 | <1% | 160 | $9K | |
| 83550 | <1% | 762 | $9K | |
| 85652 | <1% | 1,482 | $9K | |
| 83540 | <1% | 865 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 270 | $8K |
| 82077 | <1% | 276 | $7K | |
| 80354 | <1% | 195 | $6K | |
| 90715 | <1% | 291 | $6K | |
| 72131 | <1% | 31 | $6K | |
| 86664 | <1% | 370 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 320 | $6K |
| 97014 | <1% | 415 | $6K | |
| 82570 | <1% | 605 | $5K | |
| 94760 | <1% | 201 | $5K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 18 | $5K |
| 82150 | <1% | 369 | $5K | |
| 86663 | <1% | 374 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,307 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,142 | $4K |
| 82043 | <1% | 446 | $4K | |
| 73070 | <1% | 45 | $4K | |
| 71101 | <1% | 37 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 336 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 68 | $3K |
| 73560 | <1% | 66 | $3K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 20 | $3K |
| 86038 | <1% | 106 | $3K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 209 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,556 | $3K |
| 94761 | <1% | 89 | $3K | |
| 71271 | <1% | 80 | $3K | |
| 96367 | <1% | 111 | $3K | |
| 93971 | <1% | 13 | $2K | |
| 87205 | <1% | 279 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 274 | $2K |
| 86702 | <1% | 168 | $2K | |
| 87390 | <1% | 167 | $2K | |
| 84145 | <1% | 74 | $2K | |
| 85730 | <1% | 223 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 326 | $2K |
| 84550 | <1% | 212 | $2K | |
| 86431 | <1% | 110 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 41 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 32 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 32 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 665 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 227 | $1K |
| 80323 | <1% | 121 | $1K | |
| 72050 | <1% | 15 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 800 | $1K |
| 80171 | <1% | 82 | $1K | |
| 80360 | <1% | 65 | $955.34 | |
| J3490 | Unclassified drugs | <1% | 121 | $926.75 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 588 | $919.48 |
| 73140 | <1% | 17 | $889.46 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 52 | $799.61 |
| 80325 | <1% | 65 | $741.94 | |
| J2704 | Injection, propofol, 10 mg | <1% | 172 | $638.22 |
| 87075 | <1% | 29 | $637.60 | |
| 80359 | <1% | 65 | $633.01 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 148 | $629.33 |
| 80320 | <1% | 28 | $581.58 | |
| 86141 | <1% | 15 | $541.49 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 214 | $497.75 |
| 36600 | <1% | 29 | $351.81 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 232 | $341.96 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 63 | $339.41 |
| 82550 | <1% | 30 | $320.29 | |
| 80076 | <1% | 13 | $316.82 | |
| 80143 | <1% | 13 | $315.78 | |
| 87088 | <1% | 13 | $303.82 | |
| 80179 | <1% | 13 | $278.00 | |
| 83525 | <1% | 26 | $243.40 | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 14 | $208.00 |
| 80069 | <1% | 25 | $206.36 | |
| 84403 | <1% | 14 | $198.49 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 105 | $175.23 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 32 | $128.99 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 32 | $120.54 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 17 | $63.78 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 15 | $47.72 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 24 | $0.36 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 12 | $0.16 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTOCKER, TRENA (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Mercy Health Clinics, LLC | Irvine, KY | $984K |
| Mercy Health Clinics, LLC | Clay City, KY | $824K |
| Mercy Health Clinics, LLC | Beattyville, KY | $193K |
| Mercy Health-Marcum & Wallace Hospital LLC | Irvine, KY | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.